Vancouver’s Acuitas Therapeutics and Pfizer have entered into a Development and Option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development. Acuitas is focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics. […]
Acuitas
Acuitas Plays Key Role In BioNTech and Pfizer Positive COVID-19 Phase 3 Vaccine Data
BioNTech and Pfizer have announced positive efficacy data from an interim analysis of their Phase 3 COVID-19 trial results. Based on the interim analysis, the vaccine was found to be more than 90% effective in preventing COVID-19. Phase 3 of the trial encompassed testing the vaccine for safety and efficacy on 43,538 people around the […]